arrow
N

Natalia Stepien

Medical University of Vienna
H指数:9
被引数:279

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

M-PACT leverages cell-free DNA methylomes to achieve robust classification of pediatric brain tumors
2026-02-014
PRE
Impact of Bevacizumab treatment intervals on surgical interventions in pediatric neuro-oncology

贝伐珠单抗治疗间隔对儿科神经肿瘤学中手术干预的影响

2026-01-010
PRE
Robust classification of pediatric brain tumors from cell-free DNA methylomes

基于游离细胞DNA甲基组的儿童脑肿瘤鲁棒性分类

2025-11-010
OAAI
Detection of H3F3A K27M or BRAF V600E in liquid biopsies of brain tumor patients as diagnostic and monitoring biomarker: impact of tumor localization and sampling method

脑肿瘤患者液体活检中H3F3A K27M或BRAF V600E的检测作为诊断和监测生物标志物:肿瘤定位和采样方法的影响

2025-01-030
OA
Real-World Performance of Integrative Clinical Genomics in Pediatric Precision Oncology

综合临床基因组学在儿科精准肿瘤学中的真实表现

2024-12-010
OAAI
Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens
2024-11-180
PRE
Distinct relapse pattern across molecular ependymoma types

跨分子室管膜瘤类型的不同复发模式

2024-08-220
PRE
Feasibility, tolerability, and first experience of intracystic treatment with peginterferon alfa-2a in patients with cystic craniopharyngioma
2024-07-101
OAAI
FEASIBILITY, TOLERABILITY AND FIRST EXPERIENCE OF INTRACYSTIC TREATMENT WITH PEGINTERFERON ALFA-2A IN PATIENTS WITH CYSTIC CRANIOPHARYNGIOMA
2024-06-180
OAAI
ROBUST CELL-FREE DNA METHYLATION-BASED CLASSIFICATION OF PEDIATRIC BRAIN TUMOR LIQUID BIOPSIES
2024-06-180
OAAI
PRE-OPERATIVE TUMOUR CLASSIFICATION USING NANOPORE SEQUENCING OF CEREBROSPINAL FLUID
2024-06-180
OAAI
INDUCING A SENESCENCE PHENOTYPE BY BROMODOMAIN INHIBITION IN HIGH-RISK EPENDYMOMA
2024-06-180
OAAI
TOWARDS CLINICAL IMPLEMENTATION OF LIQUID BIOPSY ANALYSIS FOR PAEDIATRIC BRAIN TUMOUR PATIENTS - A PAN-EUROPEAN EFFORT FOR STANDARDIZATION
2024-06-180
OAAI
EXPERIENCE WITH THE SELECTIVE FIBROBLAST GROWTH FACTOR INHIBITOR ERDAFITINIB IN THREE PEDIATRIC PATIENTS WITH CNS TUMORS
2023-06-120
OAAI
CLINICAL RESPONSE TO THE PDGFRA/KIT INHIBITOR AVAPRITINIB IN PEDIATRIC AND YOUNG ADULT HIGH-GRADE GLIOMA PATIENTS WITH H3K27M OR PDGFRA GENOMIC ALTERATIONS
2023-06-120
OAAI